Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Automated Hematology Analyzer Assessed for Malaria Diagnosis

By LabMedica International staff writers
Posted on 11 Jun 2019
Malaria remains a major cause of morbidity and mortality around the world. More...
Sub-Saharan Africa is most affected with Plasmodium falciparum accounting for 99% of estimated cases. Timely and accurate diagnosis of malaria is essential for disease management and control.

Thin and thick blood smear microscopy and malaria rapid diagnostic tests (RDTs) are standard malaria diagnostics in endemic areas. RDTs have significantly improved the use of diagnostics for malaria diagnosis, accounting for 74% of diagnostic tests performed among suspected cases in 2015. Both techniques provide challenges in clinical practice.

An international team of scientists led by Radboud University Medical Centre (Nijmegen, the Netherlands) performed a prospective, double-blinded, phase 3 diagnostic accuracy study on 16 healthy, malaria-naive controlled human malaria infection (CHMI) participants were challenged with five P. falciparum-infected mosquitoes and a diagnostic accuracy study in Burkina Faso. Blood was sampled daily for XN-30, blood smear microscopy, and malaria quantitative polymerase chain reaction (qPCR). The XN-30 is a novel automated hematology analyzer and malaria diagnostic that directly detects and quantifies Plasmodium parasites (falciparum and non-falciparum) in blood using violet laser technology.

The team reported that all CHMI participants became parasitemic by qPCR and XN-30 with a strong correlation for parasite density. The XN-30 accurately monitored treatment and allowed detection of recrudescence. Out of 908 patients in the accuracy study, 241 had microscopic malaria (density 24–491,802 parasites/μL). The sensitivity and specificity of XN-30 compared to microscopy were 98.7% and 99.4%. Results were corrected for qPCR-confirmed sub-microscopic cases. Three microscopy-confirmed cases were not detected by XN-30. However, XN-30 detected 19/134 (14.2%) qPCR-confirmed cases missed by microscopy.

The authors concluded that the XN-30 holds promise as a rapid and sensitive test for malaria detection and subsequent treatment monitoring. Since XN-30 provides a complete blood count (CBC) with each analysis, it provides critical information for malaria management at a price comparable to CBC. Its higher sensitivity compared to microscopy in low-density parasitaemia also makes it a useful tool for mass screening in control programs. The study was published on May 31, 2019, in the journal BMC Medicine.

Related Links:
Radboud University Medical Centre


Gold Member
Hematology Analyzer
Medonic M32B
Portable Electronic Pipette
Mini 96
Gold Member
Hematology System
Medonic M16C
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.